Readouts in hepatocellular carcinoma, as well as pancreatic, gastric and salivary gland cancer, are capturing attention at ...
New-generation GLP-1 drugs, such as retatrutide, are achieving higher rates of weight loss. How much weight is too much and ...
In 2024 researchers at the University of Southern California developed an ingestible pill with optoelectronic sensors for ...
As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their drug might spur greater weight loss. Kailera is one of dozens of companies ...
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual ...
A patient displays an injection of the weight-loss drug Mounjaro on November 13, 2024. (Sebastián Hidalgo/For The Washington ...
Providers said they are encountering patients seeking treatment for anorexia, bulimia and binge eating disorder who are ...
Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.
An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet ...
An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet ...
Lilly’s new obesity drug produced roughly 28% average weight loss in trials — big efficacy, real safety and access questions.
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results